← Back to Search

Neuromodulation

Neuromodulation for Depression (TREND Trial)

N/A
Recruiting
Led By Erika E Forbes, Ph.D
Research Sponsored by Erika Forbes
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

TREND Trial Summary

This trial will study whether theta burst stimulation, a type of magnetic brain stimulation, can help reduce the severity of depression symptoms. A subset of participants will also receive positive affect training.

Who is the study for?
This trial is for individuals with a current diagnosis of depression according to the DSM-5. Participants should not have used certain drugs like cocaine or MDMA recently, have high-risk suicidality, severe substance use disorders, specific medication usage (Clozapine, Bupropion), daily nicotine use, or a history of seizures and other listed conditions.Check my eligibility
What is being tested?
The TREND study is testing theta burst stimulation (TBS) as a treatment for depression. Some participants will also receive positive affect training alongside TBS to see if it helps reduce the severity of depression symptoms more effectively.See study design
What are the potential side effects?
While the side effects are not explicitly mentioned here, similar neuromodulation treatments can sometimes cause headaches, scalp discomfort at the site of stimulation, lightheadedness or short-term changes in thinking or mood.

TREND Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
depression severity

TREND Trial Design

1Treatment groups
Experimental Treatment
Group I: TBSExperimental Treatment1 Intervention
In this open-label trial, all participants will undergo 2 continuous TBS (cTBS) sessions per visit over 10 days (weekdays, over 2 weeks; total = 20 TBS sessions in 10 visits). The total time of each pair of sessions (including pause between sessions) will be approximately 1 hour, with each session lasting approximately 100 seconds. There is only 1 group and 1 arm of the study. All participants will receive the treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Theta Burst Stimulation
2014
N/A
~140

Find a Location

Who is running the clinical trial?

Erika ForbesLead Sponsor
2 Previous Clinical Trials
304 Total Patients Enrolled
2 Trials studying Depression
304 Patients Enrolled for Depression
Erika E Forbes, Ph.DPrincipal InvestigatorUniversity of Pittsburgh

Media Library

Theta Burst Stimulation (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT05436379 — N/A
Depression Research Study Groups: TBS
Depression Clinical Trial 2023: Theta Burst Stimulation Highlights & Side Effects. Trial Name: NCT05436379 — N/A
Theta Burst Stimulation (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05436379 — N/A
~0 spots leftby Jun 2024